262 related articles for article (PubMed ID: 28649871)
21. Novel anti-angiogenic therapeutic strategies in colorectal cancer.
Tampellini M; Sonetto C; Scagliotti GV
Expert Opin Investig Drugs; 2016; 25(5):507-20. PubMed ID: 26938715
[TBL] [Abstract][Full Text] [Related]
22. The safety of ramucirumab for the treatment of colorectal cancer.
Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J
Expert Opin Drug Saf; 2018 Sep; 17(9):945-951. PubMed ID: 30073902
[TBL] [Abstract][Full Text] [Related]
23. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Papadimitriou M; Papadimitriou CA
Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
[TBL] [Abstract][Full Text] [Related]
25. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
[TBL] [Abstract][Full Text] [Related]
26. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Török S; Cserepes T M; Rényi-Vámos F; Döme B
Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
[TBL] [Abstract][Full Text] [Related]
27. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment.
Van Cutsem E; Yoshino T; Hocke J; Oum'Hamed Z; Studeny M; Tabernero J
Clin Colorectal Cancer; 2016 Mar; 15(1):91-94.e1. PubMed ID: 26603056
[TBL] [Abstract][Full Text] [Related]
28. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
29. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
30. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
Noonan S; Man Wong K; Jimeno A
Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
[TBL] [Abstract][Full Text] [Related]
31. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
32. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
Saif MW
Expert Opin Biol Ther; 2013 Nov; 13(11):1489-93. PubMed ID: 24050123
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
37. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
38. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
Expert Opin Investig Drugs; 2012 Jul; 21(7):949-59. PubMed ID: 22612461
[TBL] [Abstract][Full Text] [Related]
39. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
Loupakis F; Bocci G; Pasqualetti G; Fornaro L; Salvatore L; Cremolini C; Masi G; Danesi R; Del Tacca M; Falcone A
Curr Cancer Drug Targets; 2010 Feb; 10(1):37-45. PubMed ID: 20088795
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy.
Sun W
J Hematol Oncol; 2012 Oct; 5():63. PubMed ID: 23057939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]